ymjЯкутский медицинский журналYakut Medical Journal1813-19052312-1017ЯНЦ КМП10.25789/YMJ.2021.76.22ymj-606Research ArticleАКТУАЛЬНАЯ ТЕМАACTUAL TOPICМетаболиты триптофана в сыворотке и кале больных немелкоклеточным раком легкогоTryptophan metabolites in serum and feces of patients with non-small cell lung cancerhttps://orcid.org/0000-0002-1410-122XЗлатникЕ. Ю.ZlatnikE. Yu.

Златник Елена Юрьевна – д.м.н., проф., гл. н.с.

Author ID (Scopus): 6603160432, Author ID (РИНЦ): 327457

https://elibrary.ru/author_profile.asp?authorid=327457

г. Ростов-на-Дону

Zlatnik Elena Yurievna, MD – professor, chief researcher of laboratory of immunophenotyping of tumors

elena-zlatnik@mail.ruhttps://orcid.org/0000-0003-0874-5261СагакянцА. Б.SagakyantsA. B.

Сагакянц Александр Борисович – к.б.н., доцент, зав. лаб.

Author ID (РИНЦ): 426904, Researcher ID (WOS): M-8378-2019, Author ID (Scopus): 24329773900

г. Ростов-на-Дону

Sagakyants Alexander Borisovich – associate professor, PhD, head of laboratory of tumor immunophenotyping

Researcher ID (WOS): M-8378-2019. Author ID (Scopus): 24329773900

https://orcid.org/0000-0003-4265-1293ШатоваО. П.ShatovaO. P.

Шатова Ольга Петровна – к.м.н., доцент

AuthorID: 786647

Shatova Olga Petrovna – associate professor, PHD, Department of Biochemistry and Molecular

AuthorID: 786647

https://orcid.org/0000-0001-5389-7833ЗаболотневаА. А.ZabolotnevaA. A.

Заболотнева Анастасия Александровна – к.б.н., доцент

Zabolotneva Anastasia Alexandrovna – PhD, associate professor, Department of Biochemistry and Molecular

rsmu@rsmu.ruhttps://orcid.org/0000-0002-9032-1558АпполоноваС. А.AppolonovaS. A.

Апполонова Светлана Александровна – к.х.н., зав. лаб.

AuthorID: 153451

Appolonova Svetlana Alexandrovna – Candidate of Chemical Sciences, head of the Laboratory

AuthorID: 153451

https://orcid.org/0000-0002-7309-8913МоскалеваН. Е.MoskalevaN. E.

Москалева Наталья Евгеньевна – к.б.н., в.н.с.

AuthorID: 152176

Moskaleva Natalia Evgenievna – Candidate of Biological Sciences, leading researcher

AuthorID: 152176

https://orcid.org/0000-0002-7358-6108МешковИ. О.MeshkovI. O.

Мешков Иван Олегович – аналитик

Meshkov Ivan Olegovich – analyst of the Department of Analysis and Forecasting of Biomedical health risks

IMeshkov@cspfmba.ruhttps://orcid.org/0000-0002-7418-0222РумянцевС. А.RumyantsevS. A.

Румянцев Сергей Александрович – биохимик

AuthorID: 216741

Rumyantsev Sergey Alexandrovich – Department of Biochemistry and Molecular Biology

AuthorID: 216741

rsmu@rsmu.ruhttps://orcid.org/0000-0002-1428-7706ШестопаловА. В.ShestopalovA. V.

Шестопалов Александр Вячеславович – д.м.н., проф., зав. кафедрой

AuthorID: 92580

Shestolapov Alexander Vyacheslavovich – MD, professor, head of the department, Department of Biochemistry and Molecular Biology

AuthorID: 92580

rsmu@rsmu.ruФГБУ "НМИЦ онкологии" МЗ РоссииРоссияNational Medical Research Centre for OncologyRussian FederationЛФ «РНИМУ им. Н.И. Пирогова»РоссияPirogov Russian National Research Medical UniversityRussian FederationФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» МЗ РоссииРоссияFederal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)Russian FederationФГБУ "ЦСП" ФМБА РоссииРоссияCentre for Strategic Planning of FMBA of RussiaRussian Federation202104052025049497Copyright © Златник Е.Ю., Сагакянц А.Б., Шатова О.П., Заболотнева А.А., Апполонова С.А., Москалева Н.Е., Мешков И.О., Румянцев С.А., Шестопалов А.В., 20252025Златник Е.Ю., Сагакянц А.Б., Шатова О.П., Заболотнева А.А., Апполонова С.А., Москалева Н.Е., Мешков И.О., Румянцев С.А., Шестопалов А.В.Zlatnik E.Y., Sagakyants A.B., Shatova O.P., Zabolotneva A.A., Appolonova S.A., Moskaleva N.E., Meshkov I.O., Rumyantsev S.A., Shestopalov A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ymj.elpub.ru/jour/article/view/606

Цель работы: изучение содержания метаболитов триптофанового обмена в сыворотке крови и кале у больных НМРЛ для дальнейшей оценки возможности коррекции функционального состояния микробиоты и ее значимости в обеспечении эффективности лечения. Исследованы уровни метаболитов триптофана в сыворотке крови и кале больных НМРЛ и здоровых доноров. В сыворотке больных по сравнению с донорами показано статистически значимое снижение уровней триптофана, его доминантных метаболитов микробного происхождения, триптамина, серотонина и в тенденции – ксатнуреновой кислоты при повышении уровня хинолиновой кислоты (в тенденции). В кале больных обнаружена только тенденция к повышению уровня индола по сравнению с донорами. Мы связываем снижение уровня триптофана и его доминантных метаболитов в сыворотке больных НМРЛ, с его утилизацией опухолевыми клетками.

Our aim is to study the content of tryptophan metabolites in blood serum and feces in patients with NSCLC for further estimation of possible correction of microbiomes` functional state and its role in the providence of the efficiency of treatment. The levels of tryptophan metabolites in blood serum and feces of 100 patients with NSCLC in comparison with 100 healthy donors were studied. A number of differences were obtained: in serum of patients a statistically significant decrease in the levels of tryptophan, its` dominant metabolites of microbiotic origin - tryptamine, serotonin, downtrend for xanthurenic acid along with an increase of the levels of quinolinic acid (in tendency). In feces the levels of indole in patients had an uptrend in comparison with donors. We consider that the decrease of tryptophan and its` dominant metabolites in serum of patients with NSCLC may be due to the utilization of tryptophan by tumor cells.

немелкоклеточный рак легкогоздоровые донорыметаболиты триптофанасыворотка кровикалnon-small cell lung cancerhealthy donorstryptophan metabolitesblood serumfecesИсследование выполнено в рамках научно-исследовательской работы по договору 0373100122121000031 на выполнение научно-исследовательской работы по проекту «Изучение системы IDO1/TDO2-KYN-AhR в системе хозяин-микробиота-опухоль при злокачественных новообразованиях с целью разработки пролекарства для их лечения», от 01.06.2021 г. с ФГБУ «ЦСП» ФМБА России.The study was carried out within the framework of research work under the contract 0373100122121000031 for the implementation of research work under the project «Study of the IDO1 / TDO2-KYN-AhR system in the host-microbiota-tumor system in malignant neoplasms in order to develop a prodrug for their treatment», dated 01.06 .2021 with the Federal State Budgetary Institution «CSP» of the FMBA of Russia.ReferencesКит О.И. Молекулярно-генетические и фенотипические особенности больных аденокарциномой легкого жителей юга россии / О.И. Кит, Д.И. Водолажский, А.Ю. Максимов, Ю.Н. Лазутин [и др.] // Молекулярная медицина. - 2016. - Т. 14, № 6. - С. 35-40.Kit OI. Molecular genetic and phenotypic characteristics of patients with lung adenocarcinoma among inhabitants of the south of russia / Kit OI, Vodolazhsky DI, Maksimov AYu, Lazutin YuN [at al.] // Molecular medicine. - 2016. - Vol. 14, № 6. - P. 35-40.Особенности сопряжения кишечного и сывороточного пулов индолов при ожирении/ Шестопалов А.В., Шатова О.П., Заболотнева А.А. [и др.] // Вопросы биологической, медицинской и фармацевтической химии. – 2021.- Т. 24, № 10. - С. 3-12. Doi: 10.29296/25877313-2021-10-01Coupling features of intestinal and serum indole pools in obesity/ Shestopalov A.V., Shatova O.P., Zabolotneva A.A., Gaponov A.M., Moskaleva N.E., Appolonova S.A., Makarov V.V., Yudin S.M., Rumyantsev A.G., Roumiantsev S.A. // Problems of Biological, Medical and Pharmaceutical Chemistry. - 2021.- Т. 24, N 10. - С. 3-12. Doi: 10.29296/25877313-2021-10-01.Heyes MP. Quinolinic acid and inflammation // Ann N Y Acad Sci. 1993. - Vol. 679. - 211-6. Doi: 10.1111/j.1749-6632.1993.tb18300.xHeyes MP. Quinolinic acid and inflammation // Ann N Y Acad Sci. 1993. - Vol. 679. - 211-6. Doi: 10.1111/j.1749-6632.1993.tb18300.xHsu YL. Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis / YL Hsu, JY Hung, SY Chiang [et al.] // Oncotarget. – 2016. – Vol. 7, № 19. – P. 27584-98. Doi: 10.18632/oncotarget.8488Hsu YL. Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis / YL Hsu, JY Hung, SY Chiang [et al.] // Oncotarget. – 2016. – Vol. 7, № 19. – P. 27584-98. Doi: 10.18632/oncotarget.8488Kasper SH. Chemical inhibition of kynureninase reduces pseudomonas aeruginosa quorum sensing and virulence factor expression / SH Kasper, RP Bonocora, JT Wade [et al.] // ACS Chem. Biol. – 2016. – Vol. 11, № 4. – P. 1106–1117. Doi: 10.1021/acschembio.5b01082Kasper SH. Chemical inhibition of kynureninase reduces pseudomonas aeruginosa quorum sensing and virulence factor expression / SH Kasper, RP Bonocora, JT Wade [et al.] // ACS Chem. Biol. – 2016. – Vol. 11, № 4. – P. 1106–1117. Doi: 10.1021/acschembio.5b01082Kennedy PJ. Kynurenine pathway metabolism and the microbiota-gut-brain axis / PJ Kennedy, JF Cryan, TG Dinan [et al.] // Neuropharmacology. 2017; 112:399e412. Doi: 10.1016/j.neuropharm.2016.07.002Kennedy PJ. Kynurenine pathway metabolism and the microbiota-gut-brain axis / PJ Kennedy, JF Cryan, TG Dinan [et al.] // Neuropharmacology. 2017; 112:399e412. Doi: 10.1016/j.neuropharm.2016.07.002Lamas B. Aryl hydrocarbon receptor and intestinal immunity / B Lamas, JM Natividad, H Sokol // Mucosal Immunology. – 2018. – Vol. 11, № 4. – P. 1024-38. Doi: 10.1038/s41385-018-0019-2Lamas B. Aryl hydrocarbon receptor and intestinal immunity / B Lamas, JM Natividad, H Sokol // Mucosal Immunology. – 2018. – Vol. 11, № 4. – P. 1024-38. Doi: 10.1038/s41385-018-0019-2Lamas B. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligand / B Lamas, ML Richard, V Leducq [et al.] // Nature medicine. – 2016. – Vol. 22, № 6. – P. 598-605. Doi: 10.1038/nm.4102Lamas B. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligand / B Lamas, ML Richard, V Leducq [et al.] // Nature medicine. – 2016. – Vol. 22, № 6. – P. 598-605. Doi: 10.1038/nm.4102Lanser L. Inflammation-induced tryptophan breakdown is related with anemia, fatigue, and depression in cancer / L Lanser, P Kink, EM Egger [et al.] // Front Immunol. – 2020. – Vol. 11. – P. 249. Doi: 10.3389/fimmu.2020.00249Lanser L. Inflammation-induced tryptophan breakdown is related with anemia, fatigue, and depression in cancer / L Lanser, P Kink, EM Egger [et al.] // Front Immunol. – 2020. – Vol. 11. – P. 249. Doi: 10.3389/fimmu.2020.00249Lugo-Huitrón R. Quinolinic acid: an endogenous neurotoxin with multiple targets / R Lugo-Huitrón, P Ugalde Muñiz, B Pineda [et al.] // Oxid Med Cell Longev. – 2013. – Vol. 2013. – P. 104024. Doi: 10.1155/2013/104024Lugo-Huitrón R. Quinolinic acid: an endogenous neurotoxin with multiple targets / R Lugo-Huitrón, P Ugalde Muñiz, B Pineda [et al.] // Oxid Med Cell Longev. – 2013. – Vol. 2013. – P. 104024. Doi: 10.1155/2013/104024Mandarano M. Kynurenine/tryptophan ratio as a potential blood-based biomarker in non-small cell lung cancer / M Mandarano, E Orecchini, G Bellezza [et al.] // Int J Mol Sci. – 2021. – Vol. 22, № 9. – P. 403. Doi: 10.3390/ijms22094403Mandarano M. Kynurenine/tryptophan ratio as a potential blood-based biomarker in non-small cell lung cancer / M Mandarano, E Orecchini, G Bellezza [et al.] // Int J Mol Sci. – 2021. – Vol. 22, № 9. – P. 403. Doi: 10.3390/ijms22094403Ninomiya S. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs / S Ninomiya, N Narala, L Huye [et al.] // Blood. – 2015. – Vol. 125, № 25. – P. 3905-16. Doi: 10.1182/blood-2015-01-621474Ninomiya S. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs / S Ninomiya, N Narala, L Huye [et al.] // Blood. – 2015. – Vol. 125, № 25. – P. 3905-16. Doi: 10.1182/blood-2015-01-621474Onesti CE. Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy / CE Onesti, F Boemer, C Josse [et al.] // J Transl Med. – 2019. Vol. 17, № 1. – P. 239. Doi: 10.1186/s12967-019-1984-2Onesti CE. Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy / CE Onesti, F Boemer, C Josse [et al.] // J Transl Med. – 2019. Vol. 17, № 1. – P. 239. Doi: 10.1186/s12967-019-1984-2Schiering C. Feedback control of AHR signaling regulates intestinal immunity / C Schiering, E Wincent, A Metidji [et al.] // Nature. – 2017. Vol. 542, № 7640. – P. 242–5. Doi: 10.1038/nature21080Schiering C. Feedback control of AHR signaling regulates intestinal immunity / C Schiering, E Wincent, A Metidji [et al.] // Nature. – 2017. Vol. 542, № 7640. – P. 242–5. Doi: 10.1038/nature21080

The authors declare that there are no conflicts of interest present.